Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Current Assets (2019 - 2025)

Historic Current Assets for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $1.1 billion.

  • Beam Therapeutics' Current Assets rose 1618.27% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 1618.27%. This contributed to the annual value of $878.1 million for FY2024, which is 2748.82% down from last year.
  • Latest data reveals that Beam Therapeutics reported Current Assets of $1.1 billion as of Q3 2025, which was up 1618.27% from $1.2 billion recorded in Q2 2025.
  • Beam Therapeutics' Current Assets' 5-year high stood at $1.3 billion during Q4 2021, with a 5-year trough of $514.6 million in Q1 2021.
  • In the last 5 years, Beam Therapeutics' Current Assets had a median value of $1.1 billion in 2023 and averaged $1.1 billion.
  • As far as peak fluctuations go, Beam Therapeutics' Current Assets soared by 35107.45% in 2021, and later plummeted by 2748.82% in 2024.
  • Over the past 5 years, Beam Therapeutics' Current Assets (Quarter) stood at $1.3 billion in 2021, then decreased by 14.15% to $1.1 billion in 2022, then rose by 10.81% to $1.2 billion in 2023, then decreased by 27.49% to $878.1 million in 2024, then increased by 25.1% to $1.1 billion in 2025.
  • Its Current Assets was $1.1 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.2 billion in Q1 2025.